Microvascular Research, Journal Year: 2024, Volume and Issue: unknown, P. 104756 - 104756
Published: Oct. 1, 2024
Language: Английский
Bioorganic Chemistry, Journal Year: 2024, Volume and Issue: 146, P. 107278 - 107278
Published: March 9, 2024
Language: Английский
Citations
14
Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 3, 2025
Language: Английский
Citations
1
International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 1887 - 1908
Published: Feb. 1, 2024
Introduction: Since intrinsic ocular barrier limits the intraocular penetration of therapeutic protein through eye drops, repeated intravitreal injections anti-vascular endothelial growth factor (anti-VEGF) agents are standard therapy for neovascular age-related macular degeneration (nAMD), which highly invasive and may cause particular complications, leading to poor patient compliance. Methods: Using Penetratin (Pen) as enhancer hyaluronic acid (HA) retina-targeting ligand, a dual-modified ophthalmic liposome (Penetratin acid-liposome/Conbercept, PenHA-Lip/Conb) drop was designed non-invasively penetrate deliver anti-VEGF targeted tissue. Results: PenHA-Lip effectively penetrates targets retinal pigment epithelium via corneal non-corneal pathways. After single topical administration conbercept-loaded (PenHA-Lip/Conb), concentration conbercept peaked at 18.74 ± 1.09 ng/mL 4 h, is 11.55-fold higher than unmodified conbercept. In laser-induced choroidal neovascularization (CNV) mouse model, PenHA-Lip/Conb drops three times daily seven days inhibited CNV formation progression without any significant tissue toxicity achieved an equivalent effect injection. Conclusion: efficiently safely delivered posterior segment be promising noninvasive option nAMD. Keywords: drug delivery, liposomes, Penetratin, acid,
Language: Английский
Citations
7
European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2023, Volume and Issue: 51(5), P. 1246 - 1260
Published: Dec. 23, 2023
Language: Английский
Citations
12
Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 105 - 105
Published: Jan. 5, 2025
Branch retinal vein occlusion (BRVO) is a common vascular condition and significant contributor to vision loss worldwide, particularly in middle-aged elderly populations. This review synthesizes current knowledge on the epidemiology, pathogenesis, clinical features of BRVO, alongside recent advancements diagnostic therapeutic strategies. BRVO approximately four times more prevalent than central (CRVO) often leads impairment. By focusing this aims address specific challenges its diagnosis management. The pathophysiology complex, involving factors such as venous compression, inflammation, increased levels endothelial growth factor (VEGF). Diagnostic approaches optical coherence tomography (OCT) fluorescein angiography are highlighted for their roles assessing disease severity guiding treatment decisions. Therapeutic interventions, including laser photocoagulation, anti-VEGF therapy, intravitreal corticosteroids, critically evaluated, emphasizing emerging treatments gene peptide-based agents, small-molecule inhibitors. Despite management strategies, recurrence macular edema resistance remain challenges. Continued research essential refine protocols improve long-term visual outcomes patients with BRVO.
Language: Английский
Citations
0
Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 14, 2025
Numerous diseases, such as diabetic retinopathy and age-related macular degeneration, can lead to retinal neovascularization, which seriously impair the visual function potentially result in blindness. The presence of blood–retina barrier makes it challenging for ocularly administered drugs penetrate physiological barriers reach ocular posterior segments, including retina choroid. Herein, we developed an innovative bifunctional peptide, Tat-C-RP7, exhibits excellent penetration capabilities antiangiogenic properties aimed at treating neovascularization diseases. RP7 is NRP-1 targeting peptide that blocks vascular endothelial growth factor receptor-2 (VEGFR-2) signaling inhibits angiogenesis, while Tat facilitates delivery various cargoes across biological barriers, barrier. By combining these attributes, Tat-C-RP7 anticipated traverse via topical administration exert its effects segment. Experimental results demonstrated significantly inhibited proliferation migration rat microvascular cells effectively reduced tubule formation vitro. Its activity was confirmed zebrafish. outstanding penetrative FITC-labeled have been validated through cell uptake assays, vitro models, ex-vivo tissues, vivo studies. Besides, half-life longer than RP7. In oxygen-induced model, shown reduce area angiogenesis following administration. Additionally, produced no irritating on eyes rabbits. Overall, demonstrates penetrability represents a promising therapeutic option
Language: Английский
Citations
0
Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 265 - 265
Published: Feb. 17, 2025
Background: Sirtuin-1 (SIRT1), a histone deacetylase enzyme expressed in ocular tissues with intracellular localization, plays critical protective role against various degenerative diseases. The link between reduced SIRT1 levels and diabetic retinopathy (DR) has prompted the exploration of natural therapeutic compounds that act as agonists. Curcumin (CUR), which been shown to upregulate expression, is one such promising compound. However, effective delivery CUR deeper tissues, particularly retina, remains challenge due its poor solubility limited penetration following topical administration. Within this context, development self-nanoemulsifying drug systems (SNEDDS) for represents novel approach. Methods: In accordance our prior research, optimized SNEDDS loaded were developed characterized post-reconstitution simulated tear fluid (STF) at 1:10 ratio, showing suitable physicochemical technological parameters delivery. Results: An entrapment efficiency (EE%) approximately 99% an absence precipitation noticed upon resuspension STF. CUR-SNEDDS resulted better stability release profile than free under conditions. vitro analysis mucoadhesive properties revealed CUR-SNEDDS, modified cationic lipid, demonstrated enhanced interactions mucin, indicating potential improved retention. Cytotoxicity tests did not affect viability human corneal epithelial (HCE) cells up concentrations 3 μM displayed superior antioxidant activity compared oxidative stress model using retinal pigment (ARPE-19) exposed hydroquinone (HQ). Cell uptake studies confirmed accumulation within exposure neat CUR. lower concentrations, found effectively induce expression. Conclusions: cytocompatibility, properties, cellular suggest these hold promise formulations retina.
Language: Английский
Citations
0
Theranostics, Journal Year: 2024, Volume and Issue: 14(9), P. 3509 - 3525
Published: Jan. 1, 2024
Current treatments for ocular angiogenesis primarily focus on blocking the activity of vascular endothelial growth factor (VEGF), but unfavorable side effects and unsatisfactory efficacy remain issues. The identification novel targets anti-angiogenic treatment is still needed.
Language: Английский
Citations
3
Heliyon, Journal Year: 2024, Volume and Issue: 10(8), P. e29984 - e29984
Published: April 1, 2024
Corneal neovascularization (CoNV)is a major cause of blindness in many ocular diseases. Substantial evidence indicates that vascular endothelial growth factor (VEGF) plays an important role the pathogenesis corneal neovascularization. Previous showed artemisinin may inhibit angiogenesis through down regulation VEGF receptors. We designed and synthesized derivatives, validated their inhibitory effect on cell animal models, explored mechanisms by which they exert CoNV. Among these P31 demonstrated significant anti-angiogenic effects vivo vitro. Besides, inhibited VEGF-induced HUVECs rabbit model via AKT ERK pathways. Moreover, alleviated angiogenic inflammatory responses suture cornea. In conclusion, as novel derivative, attenuates has promising application
Language: Английский
Citations
1
International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: unknown, P. 124700 - 124700
Published: Sept. 1, 2024
Language: Английский
Citations
1